Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Change in Accured Expenses (2020 - 2025)

Rapid Micro Biosystems' Change in Accured Expenses history spans 6 years, with the latest figure at $599000.0 for Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 169.25% year-over-year to $599000.0; the TTM value through Sep 2025 reached -$1.5 million, down 171.71%, while the annual FY2024 figure was -$3.9 million, 371.27% down from the prior year.
  • Change in Accured Expenses for Q3 2025 was $599000.0 at Rapid Micro Biosystems, up from $335000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $2.9 million in Q4 2023 and bottomed at -$3.9 million in Q1 2022.
  • The 5-year median for Change in Accured Expenses is -$341000.0 (2021), against an average of -$209473.7.
  • The largest annual shift saw Change in Accured Expenses crashed 396.8% in 2022 before it surged 28860.0% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at -$341000.0 in 2021, then skyrocketed by 102.93% to $10000.0 in 2022, then soared by 28860.0% to $2.9 million in 2023, then tumbled by 115.16% to -$439000.0 in 2024, then skyrocketed by 236.45% to $599000.0 in 2025.
  • Per Business Quant, the three most recent readings for RPID's Change in Accured Expenses are $599000.0 (Q3 2025), $335000.0 (Q2 2025), and -$2.0 million (Q1 2025).